Studies indicate that a modified variety of CBD possesses strong anti-inflammatory and antioxidant properties that are likely to aid in treating epidermolysis bullosa. For your information, the term ‘epidermolysis bullosa’ refers to a set of uncommon skin disorders that are inherited. Going by what the study reveals, CBD for EB is potentially useful.
CBD is among the most-researched cannabis-based phytocannabinoids. It lacks a mind-altering effect but has inflammation-reducing and antioxidative properties. These properties cause CBD to be a more and more interesting treatment option for many disorders, which include EB. Now, does this mean you should seek CBD for epidermolysis bullosa? Here, we will help you to answer it.
What Do Researchers Say?
In a recent study, the Spain-based University of Cordoba’s and the Scotland-based University of Dundee’s research professionals incubated keratinocytes with cannabidiol for a day. After that, they compared those epidermal skin cells with the cells that are not treated and that serve as components for comparison.
The researchers checked in what way proteome and transcriptome changed following treatment through cannabidiol. Their analysis showed that cannabidiol might just encourage the processes of keratinocytes maturing and increasing in number, plus the pathways essential for skin growth. People who were part of this study confirmed these kinds of effects in mice.
HMOX1 was among the genes that cannabidiol made active. The enzyme, heme oxygenase has inflammation-reducing and antioxidant properties related to the skin. More experiments revealed that cannabidiol caused the process of the BACH1 protein being degraded. It is a protein that works in the form of an HMOX1 repressor. Huntington’s chorea cell models revealed that this variety of cannabidiol not only possess antioxidant properties but that it is also possibly useful in tackling certain effects of getting older. For your information, a lack of balance between antioxidant defenses and the creation of possibly dangerous reactive oxygen species, causes oxidative stress.
“When combining the inhibition of BACH1 with the activation of NRF2, the result is a very potent antioxidant and anti-inflammatory response and better therapeutic effects,” stated Eduardo Muñoz, who led the Spain-based university’s group of researchers.
The planned research involves continuously tweaking the molecules derived from cannabidiol and testing these in the animal models with inflammation-related disorders. Skin diseases are among these inflammatory disorders.
The work at this Spanish university resulted in the making of Innohealth Madrid and Emerald Health Biotechnology. These two companies played a part in the first steps of this research.